l It has been demonstrated that the level of serum copper unbound to ceruloplasmin (loosely bound copper) is increased in Wilson' s disease, although the total serum copper concentration is usually low, reflecting a low ceruloplasmin level. To assess the contribution of free radical reactions catalyzed by nonceruloplasmin copper to the development of complications in this disease, we investigated copper and antioxidant status in four untreated patients who had hepatic dysfunction with or without hemolytic anemia and made a comparison with five patients controlled on penicillamine therapy and 19 age-matched healthy children. We found that loosely bound copper in plasma measured by the phenanthroline assay was detectable in three of four untreated patients with Wilson's disease, but was not detectable in the patients during therapy or in the healthy controls. Among the various antioxidants, the ascorbate and urate levels were markedly reduced before treatment (mean =SO, 23 =16 JLM for ascorbate and 90 =59 JLM for urate) compared with the values in the patients during treatment with penicillamine (67 =19 and 302 =78 JLM, P < 0.05) and in control children (60 =8 and 254 =48 JLM, P < 0.05). We also demonstrated that the plasma concentration of allantoin, an oxidation product of uric acid and a possible marker of radical generation in vivo, was markedly elevated in the untreated patients (11.0 ± 1.8 versus 4.3 =0.5 JLM in patients on therapy and 6.5 =0.8 JLM in controls, p < --------------0.05). The low plasma urate level together with the elevation of allantoin were thought to be responsible for the degradation of uric acid as a sacrificial antioxidant. In contrast, the plasma levels of a -tocopherol and thiobarbituric acid reactive substances did not differ in these three groups. The value of the total radicaltrapping antioxidant parameter was reduced in the patients before the initiation of therapy (372 ± 146 versus 942 =79 JLM in patients on therapy and 856 =104 JLM in controls, p < 0.05), and this was mainly attributed to the depiction of ascorbic acid and uric acid. These findings suggest that the elevation of loosely bound copper leads to transition metal catalyzed free radical reactions in the aqueous phase of plasma, which may play a role in the clinical complications of Wilson's disease. (Pediatr Res 37: 219-226, 1995) Abbreviations TBARS, thiobarbituric acid reactive substance AAPH, 2,2' -azobis (2-amidinopropan e) dihydrochlorid e TRAP, total radical-trapping antioxidant parameter TRAPmeas , experimentally measured TRAP TRAPcalc, theoretically calculated TRAP TRAPdijf, difference between TRAPmeas and TRAPcalc GPT, glutamic pyruvic transaminase Wilson ' s disease is an inherited disorder of copper metabolism characterized by the defective biliary excretion of copper and impairment of its incorporation into ceruloplasmin. These defects result in the accumulation of copper in the liver with progressive hepatic damage and subsequent redistribution to various extrahepatic tissues including the brain, kidneys, and cornea (1, 2) . Although the total serum copper concentration is not always high in Wilson 's disease due to a low ceruloplasmin level (1), the nonceruloplasmin copper level is still expected to be high (3, 4) . In particular, tissue copper may be released into the circulation in massive amounts during episodes of acute liver insufficiency, and the nonceruloplasmin copper level is thought to be comparable to that seen in acute copper poisoning (1). However, elevation of the nonceruloplasmin copper level in Wilson's disease has generally been assumed on the basis of calculation of the difference between the saturation copper binding to ceruloplasmin (six atoms per molecule) and the total serum copper concentration , and direct measurement of free plasma copper levels has only been performed in a few studies (5) . In our study, we attempted to measure loosely bound copper levels in plasma directly using a sensitive phenanthroline assay (6) to confirm that those levels were actually increased in untreated patients.
Free radical production by reactions involving plasma nonceruloplasmin copper has been proposed as the cause of acute hemolysis and multiple organ insufficiency in association with 220 OGIHARA ET AL. severe liver damage in Wilson 's disease (7) , but this has not been proved. If copp er ions released from the liver into the blood catalyze the generation of free radicals, the consumption of radic al-trapping plasma antioxidants might be a possible initial event. To assess the antioxidant status III Wilson's diseas e, we measured ascorbic acid, sulfhydryl groups, and uric acid as plasma aqueous antioxidants and a-tocopherol as an antioxidant in the plasma lipid phase. Togeth er with ascorbic acid, uric acid is thought to be one of the major antioxi dants in plasma (8) , and it acts as a sacrificial radical scavenger with the resultant generation of oxidation product s such as allantoin (9) . Therefore, the measurement of allantoin might be a proposal " marker" of free radical generation in vivo (10) . With this in mind, we additionally measured the plasm a allantoin concentration in Wil soni an patients and compared it with that in age-m atched healthy children.
The total antioxidant capacity of plasma is dependent on the synergism between various antioxidants (11) in addition to the capaci ty of each single antioxidant actin g alon e. Alth ough a test has been developed to measure the TRAP of plasma (12) , these potenti ally important interactions have only been explored in a few clini cal studies (13) (14) (15) . In this stud y, we also measured the TRAP value to evaluate the total plasma antioxidant capacity in Wilsonian patients. In addition, we investigated the change with time in all the parameters mentioned above in two patients with Wilson's disease before and during penicillamine therapy.
METHODS

Subjects
We investigated four patients with Wilson 's disease before starting penicillamine therapy (two boys and two girls; mean age 10.5 y), five Wilsonian patients durin g therap y (four boys and one girl; mean age 12.5 y, including two of the patients examined before ther apy), and 19 age-m atched control s (seven boys and 12 girls; mean age 12.3 y) who attended our outpatient clinics either for health checks or with various minor sympt oms such as fever, cough, headache, and motion sickness. The study proto col was approved by the ethical committee of our college hospit al and the studies we re performed after inform ed consent was obtained. The diagnosi s of Wilson 's diseas e (16, 17) was confirm ed in all patients on the basis of clini cal features and their copp er metabolism , i.e. a low serum ceruloplasmin level « 1.5 fLM), a low serum copper concentration «12 fLM), a high urinary copp er excretion, both basal (> 1.5 fLM/d) and after oral D-penicillamine (>25 fLM/d), and/ or elevated concentration of liver copper (>250 fLgl g dry weight). The laboratory data of the patients are summarized in Table 1 , and detail s of clinic al courses are given below. Patient 1. A previously well lO-y-old girl occas ionally passed tarry stool for about 6 mo. She developed malaise and nausea, and she vomited " coffee grounds" liquid 2 wk befor e admission. On admission to our hospital, she was found to have hep atom egaly, with the liver edge palpable 3 cm below the costal margin, and abdominal disten sion due to ascites. Laboratory tests showed anemi a, but hemolysis was not obvious because of a norm al haptoglobin level (220 mgldL) and no hyperbilirubinemia. Coagulation was impaired, with a prolonged prothrombin time and reduction of the thrombotest to 22.5% of the normal level. Liver biopsy showed cirrhotic change with patchy necrosis, many regenerating nodules, and excessive deposition of copper with an elevated liver copper concentration. Treatment was initiated with penicillamine, and the dose was 1000 mg/d at 30 mo after admission when the plasma sample during therapy was obtained. Zinc sulfate (600 mg/d) was added from 6 mo after the start of therapy due to prolonged mild elevation of the transaminases. She recovered fully within an 8-mo period.
Patient 2. A previously healthy 12-y-old boy was admitted to our hospital because of painful pretibial edema, abdominal distention, and malaise lasting for about 1 wk. Physical examination revealed ascites and jaundice without hepatosplenomegly. Hemolysis was evidenced by mild anemia with a reticulocyte count of 11.2%, hyperbilirubinemia, negative direct and indirect Coombs' tests, and a low haptoglobin level «30 mg/dL). A clotting abnormality was demonstrated with a prolonged prothrombin time, reduction of the hepaplastin test to 25% of normal, and thrombotest reduction to 32% of normal. Liver biopsy showed fatty change, mild enlargement of the portal tracts with fibrosis and infiltration, and excessive copper deposition with a raised hepatic copper level. He was started on penicillamine, and the dose was increased to 800 mg/d at the time when the plasma sample during therapy was taken. A gradual improvement of both clinical and biochemical parameters was observed.
Patient 3. A 12-y-old girl had developed elevated transaminase levels 2 y previously and was followed up thereafter. When she was admitted to the Wakayama Medical School Hospital for further workup, slit lamp examination of the eyes demonstrated corneal Kayser-Fleischer rings and liver biopsy revealed early cirrhosis with marked elevation of the hepatic copper content. She was diagnosed as having Wilson's disease and was immediately started on penicillamine therapy. Three mo later, while the penicillamine dose was being gradually increased with monitoring of urinary copper excretion, she experienced fatigability accompanied by jaundice and was readmitted. Her general condition deteriorated rapidly leading to coma. Laboratory tests provided evidence of Coombs'< negative hemolytic anemia as demonstrated by indirect hyperbilirubinemia and a low haptoglobin level «30 mg/dL) as well as severe coagulation abnormalities (a markedly prolonged prothrombin time and a hepaplastin test that was only 20% of normal). She underwent frequent exchange transfusion or total plasma exchange, and triethylene tetramine dihydrochloride and dimercaprol were given together with penicillamine. Despite intensive cares, she died of combined hepatic and renal failure at 2 mo after readmission.
Patient 4. An S-y-old boy attended our hospital with fever and cough due to a viral infection. Elevation of the transaminases was unexpectedly detected and he was admitted for further evaluation of liver function. The liver edge was palpable 2 em below the right costal margin. Studies of his copper metabolism suggested Wilson's disease and the diagnosis was confirmed by elevation of the hepatic copper content with fatty change and intralobular spotty necrosis. Immediately after the definitive diagnosis, treatment with penicillamine (300 mg/d) was instituted. However, penicillamine was discontinued at a dose of 400 mg/d due to fever and was changed to Trientine at 2 mo after admission.
Patient 5. A lO-y-old-boy was admitted with a 3-d history of frequent vomiting and jaundice. Before this illness, a preliminary diagnosis of chronic hepatitis with elevation of the transaminases had been made and follow-up had continued. His parents were consanguineous. On examination, he was icteric, the liver edge was 4 em below the costal margin, and corneal Kayser-Fleischer rings were found. Within 1 wk, he developed signs of fulminant hepatitis leading to coma. Laboratory tests showed marked elevation of the transaminases (glutamic oxaloacetic transaminase, 3720 IU; GPT, 1086 IU), hemolysis (Hb, 5.2 g/dl.; reticulocyte count, 32.8%; indirect bilirubin, 19 mg/dL; and haptoglobin, <30 mg/dL), and severe clotting abnormalities (prothrombin time, 21%; thrombotest, 30% of normal). Abnormalities of copper metabolism were also noted that were characteristic of Wilson's disease. The liver biopsy showed precirrhotic liver with irregular regenerating nodules, and copper staining was positive. Frequent exchange transfusion with penicillamine treatment dramatically improved his clinical status. Within 3 wk, his symptoms almost disappeared, and the transaminase levels improved after 2 mo. At the age of 14, a plasma sample was taken for this study during treatment with penicillamine at 1200 mg/d.
Patient 6. An 8-y-old-boy, whose sister and first cousin had Wilson's disease, developed fatigue for 2 mo. Anorexia and nausea ensued 1 mo later and he became jaundiced 2 wk before admission. Physical examination revealed ascites and hepatomegaly (liver edge 2 cm below the costal margin). Laboratory tests showed abnormal liver function with a glutamic oxaloacetic transaminase of 51 IU, a GPT of 63 IU, and a direct bilirubin of 18 mg/dL. A diagnosis of Wilson's disease was made on the basis of abnormal copper metabolism, the presence of Kayser-Fleischer rings, and a positive family history. He began treatment with penicillamine, and the jaundice disappeared within 3 wk. The plasma sample was taken at the age of 12 during treatment with penicillamine at a dose of 600 mg/d. Patient 7. A 9-y-old boy in previously good health developed nausea and vomiting. He was found to have raised transaminase levels by his family doctor and was referred to our hospital. The liver edge was 3 em below the costal margin, but no jaundice was noted. Laboratory data were not striking, except for a GPT level of 53 IU. Slit lamp examination revealed Kayser-Fleischer rings, and data on his copper metabolism were compatible with Wilson's disease. Therapy with penicillamine was instituted 10 d after admission. The plasma sample was obtained at the age of 12 during treatment with penicillamine at 1000 mg/d.
All of these patients had the hepatic form of Wilson's disease: patients 3 and 5 had the fulminant hepatitis type and the others had the acute hepatitis type. Hemolysis was present in patients 2 and 3. Patient 5 was also in hemolytic crisis before the initiation of therapy. None of the patients had any neurologic symptoms. Heparinized blood samples were immediately centrifuged (1000 X g, 10 min), and the plasma was stored under nitrogen gas at -80°C until analysis within 4 wk. Preliminary studies confirmed that the TRAP value, the levels of various antioxidants, and the phenanthroline-detectable copper level did not change within 6 mo after plasma samples were taken (data not shown).
Determination of Plasma Antioxidants
The plasma a-tocopherol level was measured by a modification of the method of Ishibashi et al. (18) , using HPLC with electrochemical detection as described in our previous paper (19) . The instruments used were as follows: an IRICA~-871 HPLC (Irica Instruments Inc., Kyoto, Japan); an IRICA RP-18T (octadecylsilane) 4 X 250 mm column; methanol/water/ NaCI0 4 eluent at a ratio of 1000/2/7 (vol/vol/wt) and a flow rate of 1.0 mlzrnin; and an IRICA Amperometric~-875 detector with an applied voltage of 700 mV.
Determination of plasma ascorbate and urate levels was carried out using a slight modification of the method of Iriyama et al. (20) . In brief, 0.1 mL of plasma was mixed with 0.9 mL of an aqueous solution containing 10% metaphosphoric acid and 20 mM deferoxamine mesylate, and the mixture was centrifuged at 3000 X g for 10 min at 4°C. A lO-fLL aliquot of the supernatant was injected directly into the same HPLC system equipped with electrochemical detection used for a-tocopherol detection except that the eluent was 0.2 M KH Z P0 4 -H 3P04 (pH 3.0) containing 50 fLM EDTA.
The total plasma sulfhydryl concentration was measured by Ellman's method (21) .
Determination of Allantoin
Allantoin analysis was carried out based on a slight modification of the method described by Grootveld and Halliwell (10) . Separated plasma was deproteinized with a 1/10 volume of 100% trichloroacetate, and an 80-fLL aliquot of the supernatant was injected directly into an IRICA SCX-101O ionexchange column (4 X 250 mm), with a mobile phase of 60 mM KH Z P0 4 adjusted to pH 3.0 with HCI at a flow rate of 1.0 mlzmin. The HPLC system was identical to that used for antioxidant determinations. A fraction covering the retention time range from 2.0 to 6.5 min, where allantoin was known to be eluted, was collected and then evaporated to dryness at 40°C under vacuum. The residue was reconstituted in 300 fLL of 3 M NaOH and heated in a boiling water bath for 20 min, then treated with 200 fLL of 5 M HCI followed by 30 fLL of a 3 mM solution of 2,4-dinitrophenylhydrazine in 1 M HCl with heating for 10 min. After the mixture had been allowed to cool, an 80-fLL aliquot was injected into an octadecylsilane column identical to that used for determining plasma antioxidants. The mobile phase was 70% (vol/vol) 30 mM sodium citrate/27.7 mM sodium acetate buffer (pH 4.75) and 30% (vol/vol) methanol at a flow rate of 1.0 ml./min. Glyoxylate 2,4-dinitrophenylhydrazone was detected as the allantoin derivative at 360 nm with a Shimadzu SPD-8AV spectrophotometer (Shimadzu Corp., Kyoto, Japan). A linear standard curve in the range from 1 to 100 fLM was obtained by treating a series of allantoin (nacalai tesque Inc., Kyoto, Japan) dissolved in 10% trichloroacetate in the same way as the samples. The plasma allantoin concentration was quantified by comparing the peak area of glyoxylate 2,4-dinitrophenylhydrazone with values from the standard curve. The recovery of three different concentrations of added allantoin (10, 25, and 50 fLM) to plasma averaged 91.6% in five replicate analyses of each plasma sample. The mean coefficient of variation for analysis of eight replicate plasma samples was 2.2%.
Measurement of TBARS
The plasma TBARS level was measured according to the method of Yagi (22) , and TBARS values were calculated against a known amount of tetraethoxypropane as the standard.
Measurement of Ceruloplasmin
The serum ceruloplasmin level was measured by nephelometry (23) and expressed in fLM by assuming a molecular weight of 132000.
Measurement of Copper
The total plasma copper concentration was determined by atomic absorption spectrophotometry (24) . The level ofloosely bound copper in plasma was measured by the phenanthroline assay (6). 1,1O-Phenanthroline is known as a chelating agent that shows a specificity for copper ions, and this assay is based on the fact that a phenanthroline-copper ion complex degrades DNA in the presence of a reducing agent to yield a thiobarbituric acid-reactive chromogen. On the basis of this reaction, a sensitive and specific assay for loosely bound copper in plasma has been established. Loosely bound copper, such as copper ions attached to albumin or amino acids, is available for chelation by phenanthroline, but copper incorporated into ceruloplasmin is not. Inasmuch as penicillamine does not affect the ability of copper ions to react with phenanthroline, penicillamine-copper complexes should also be measurable with this assay (5). The phenanthroline assay was performed exactly as described in the literature (6) using a HITACHI F-3000 fluorescence spectrophotometer (Hitachi Ltd., Tokyo, Japan). The level of loosely bound copper in plasma was estimated from the fluorescence intensity on the basis of a standard curve for copper concentrations ranging from 1 to 10 fLM, which was established using CuClz'
TRAP Assay
The TRAP of plasma was measured according to the method of Wayner et al. (12) . The oxidation of linoleic acid in the presence of plasma was induced by AAPH at 37°C in 20 mM phosphate buffer (pH 7.4) containing 1 mM EDTA and was monitored by following the oxygen consumption using an Oxygraph model 5/6 (Gilson Medical Electronics Inc., Middleton, WI). AAPH generates initiating radicals in the aqueous phase by unimolecular thermal decomposition, and the rate of initiation can be easily controlled by adjusting the concentration and temperature (25, 26) . The oxidation of linoleic acid was initially inhibited by plasma antioxidants to form an induction period and then progressed rapidly. The duration of the induction period was determined to quantify the TRAP value by using the duration produced by a known quantity of a water-soluble analogue of tocopherol , 6-hydroxy-2,5,7,8-tetrameth ylchroman-2-carboxylic acid (Trolox; Hoffman-La Roche, Nutley, NJ) and the stoichiometric factor, n = 2. Values obtained in this assay were expressed as TRAPmeas in terms of iLM. TRAP was also calculat ed stoichiometrically (TRAPcalc) from the concentrations of plasma antioxidants using the experimentally determined stoichiometric factors (n) and the following equation (12) 
Statistical Analysis
The statistical significance of differences between groups was evaluated with nonparametric Mann-Whitney V test. p < 0.05 was considered to be significant.
RESULTS
As shown in Table 1, the loosely bound copper level measured by the phenanthrolin e assay was increased up to a detectable level in patients 1, 2, and 3. Conversely, the patients well-controlled on penicillamine as well as the age-matched healthy children had no detectable loosely bound copper in plasma. In patients 1 and 2, loosely bound copper also dropped to undetectable levels after the initiation of penicillamine therapy.
Among the four major plasma antioxidants measured in this study (ascorbic acid, uric acid, sulfhydryl groups, and a -tocopherol), the reduction of uric acid in untreated patients was the most notable followed by ascorbic acid, both of which reached statistical significance compared with the patients during therapy and the healthy controls (Table 2 ). In addition, the allantoin concentration was elevated more than 2-fold and the ratio of allantoin to uric acid was increased about lO-fold in the patie nts before the initiation of therapy when compared with the well-controlled patients and the healthy children (Table 3) . Protein sulfhydryl groups also tended to be lower in the untreated patients, but the difference did not reach statistical significance. In contrast, the a -tocopherol concentration and the TBARS level were similar in the untreated patients, the patients receiving therapy, and the controls. The ratio of atocopherol to total plasma lipids (the sum of total cholesterol, triglycerides, and phospholipid s), which is considered to be the most reliable index for the assessment of vitamin E status (27) , also showed no significant difference in the three groups (mean ± SD: untreated patients, 1.86 ± 0.83 iLglmg; patients receiving therapy, 1.67 ± 0.36 iLglmg; controls, 1.64 ± 0.12 iLglmg) . The TRAPmeas value in the patients without therapy was significantly lower than in the other two groups, which may have mainly reflected the low plasma levels of uric acid and ascorbic acid. The difference between TRAPmeas and TRAPcalc (i.e. the TRAPdijf level) was also significantly smaller in the untreated patients.
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OGIHARA ET AL. D-Penicilla mine (mg/ day ) Figures 1 and 2 represent the clinic al course of patients 1 and 2, respectively, both before and during penicillamine therapy. In both patients, after the start of therapy, the initially reduced urate concentration gradually increase d to a level comparable to that in the controls, and a similar trend was observed for the ascorbate level. In contrast, the elevated allantoin level decreased to the norm al range and the loosely bound copper level also decreased to become undetectable (data not shown). In associ ation with the increase of antioxidant levels during therapy, a gradual increase of the TRAPmeas value was observed in both patients. copper decreased to an undetectable level comparable to that in the patients well controlled on penicillamin e. Similarly, Evans et al. (5) have reported that no phenanthroline-detectable copper could be measured in serum freshly prepared from patients with uncomplicated Wilson's disease, whereas it could be measured in serum fro m a patient with fulminant hepatic failure.
It has been widely recognized that trace amounts of transition metals including copper and iron play a major role in oxidant-induced tissue injury through part icipation in the generation of active oxygen species and facilit ation of lipid peroxidation (30) . It is possible that copper ions catalyze the oxidation of ascorbic acid or sulfhy dryl group s, in the process reducing molecular oxygen to generate reduced oxygen metabolites such as superoxide and hydrogen peroxide, leading to form ation of the highly reactive hydroxyl radical by a mechanism analogous to the Harber-Weiss chemical reaction (31) . If loosely bound copper released from the liver catalyzes the generation of free radic als in circ ulation, the consumption of radical-trapping plasma antioxidants is likely to be an initial event.
In hum an plasma, ascorbic acid and uric acid are among the most widely cited forms of water-soluble antioxidants and appear to serve as the main defense against oxidizing species in the aqueous phase (32) . Uric acid showed the greatest decrease amonz the various plasma antioxidants in untreated patients with Wilson 's disease in our study, and this was accompanied by elevation of the allantoin concentration . During the course of human evolution, the plasma urate level has increased markedly as a consequence of the loss of uricase activity, which further metabolizes uric acid to allant oin (33) . Am es et al. (8) have prop osed that, with the accompanying loss of ascorbate synthesis , uric acid may have repl aced some of the antioxidant functions of ascorbic acid. Uric acid is an end product of purine metabolism in hum ans, and it may act as a sacrificial antioxidant against hydrox yl radicals , peroxyl radicals, hypochrolous acid, and other hazardous oxidants, with the Wilson 's disease is know n to be caused by genetic defects in the copper transport mechanism (16) . One of the essential defects is thought to be impaired biliary excretion of copp er (28) , which leads to copper accumulation in the liver and subsequent redistribution to the brain, causing liver insufficiency from late childhood onward and neurologic symptoms in mid-adult life (1, 2) . The incorporation of copp er into ceruloplasmin is also impaired in patients with Wilson 's disease, so the serum concentrations of cerulop lasmi n and copper are usually low (2) . In the normal state, about 96% of serum copper is associated with ceruloplasmin. Therefor e, the red i~ tribu tion of copper to extrahepatic tissues is likely to occur via plasma nonceruloplasm in copper, which means copper ions released into the circulation from damaged hepatocytes that becom e attached to albumin or amino acids (29) .
Gutterridge (6) developed a phenanthroline assay that can measure nonceruloplasmin copper down to a sensitivity of 0.1 /-LM. Using this sensitive method, we have provided eV i den~e that the loose ly bound copp er level in plasma was elevated III three patie nts with Wilson 's disease before the initiation of penicillamine therap y. Alth ough one of them died of fulminant hepatitis, the other two improved after penicillamine therapy was initiated, and their plasma conce ntrations of loosely bound resulta nt generation of oxidation products such as allantoin (9) . It has there fore been propo sed that allantoin might be a "marker" of oxidant generation in vivo. Indeed, an increased allantoin concentration has been reported in both plasma and knee -joint synovial fluid obtained from patients with rheum atoid arthritis (10) . In our study, we demon strate d a marked elevation of the plasma allantoin concentration and the ratio of allantoin to uric acid in patients with Wilson 's diseas e before the initiation of therap y together with severe urate depletion . Conversel y, in the well-controlled patients who had been treat ed wit h penicillamine, the levels of uric acid and allantoin were comparable to those in health y age-matched children. Based on these results, we speculate that free radical reactions catalyzed by loosel y bound copp er take place in patients with Wilson 's disease who fell into pathologic conditions as a consequence of the release of copper from the liver.
Urinary urate clearance in patients with Wilson 's disease was previou sly reported to be increased when compared with that in health y controls (34) . However, we found that the four untreated patients who we re tested showed no significant difference in urinary urate clearance (mean ± SD , 12.0 ± 2.9 mlzmin/rrr') comp ared with 10 age-matched controls (11.4 ± 4.0 ml.zmin/m/). Fract ional excretion of uric acid in untreated patients (mean ± SD, 0.13 ± 0.04) did not differ from that in controls (0.13 ± 0.05). Therefore, it is possible that the hypouricemi a in untreated patients was deriv ed from urat e consumption as an antioxidant rather than from excessive urinary loss.
The plasma ascorbate level was considerably depleted in the untre ated patients, and the concentration of sulfhydryl groups was sometimes also decr eased . It is widely accepted that ascorbic acid is one of the major aqueous antioxidants in human plasma (35) . The decrease of ascorbic acid and sulfhydryl group s in the patients with Wilson 's disease may have resulted from their antioxidative degradation, as in the case of uric acid. However, in the presence of transition metals, ascorbic acid and sulfhydryl groups are readily oxidized to generate oxygen radic als and other radical species (36, 37) . Accordingly, it is also possible that ascorbic acid and sulfhydryl groups acted as prooxidants rather than antioxidants in the untreated patients .
In contrast, no significant consumpti on of a -tocopherol was observed even in the untreated patients. Inasmuch as a-tocopherol is the major chain-breaking antioxidant in the lipid phas e, in the case where free radicals were produced in the aqueous phase, water-soluble ch ain-breaking antioxidants wo uld be preferentially consume d (12, 32) . The fact that the plasma TBARS level , which has been suppos ed as an ind ex of lipid peroxidation, remain ed within the normal range also indicates that lipid pero xidation may not contribute much to the oxidative damage that occur s in Wilsoni an patient s. However, these finding s cannot rule out the possibility that coppe rinduced lipid peroxidation takes place in other tissues, as demonstrated in the livers of copper-overloaded rats (38) . Recent investigations have indicated that plasma antioxidants show synergic interactions in vivo so as to provide gre ater protection against radic al dam age than could be achieved by any single antioxidant acting alone (12) . For exampl e, it is well established that ascorbic acid can synergisticall y regenerate a -tocopherol (11) , and it has also been suggested that uric acid can inhibit ascorbate autooxid ation in plasma by formation of stable metal-urate complexes (39) . Therefore, a precise understanding of the total plasma antioxidant capacity will require an estim ation of the combined effect of va rious antioxidants in addition to measurem ent of the individu al antioxidants. Wayner et al. (12) developed a test to estim ate the TRAP of hum an plasm a and examined the relative importance of each antioxidant. Acc ordin g to the TRAP assay, we found that TRAPmeas values were profoundly reduced in the patients with Wilson 's disease befor e penicillamine therapy when compared with the values in the patients rece iving therapy and in the healthy children. This decrease of TRAPmeas values seemed to be attributable mainly to the low plasma levels of uric acid and ascorbic acid . The T RAP calc values were always lowe r than the TRAPmeas values, and the most prob able explanation for this finding is that TRAPcalc does not take into account the interactions between various antioxidants (11, 12, 40) . Anoth er possible explanation for the remaining gap is that not all the plasma antioxidants were identified and con sidered. However, although bilirubin, J3-carotene, and ubiqu inol have been recognized as important antioxidants, their concentrations are too low to account for a larg e unidentified antioxidant component (13) .
In recent studies , the TRAP assay has give n usefu l information about plasma antioxidant activit y in newborn babies (13) and patients with cystic fibrosis (15) . However, it has been pointed out that the TRAP assa y is not a good mod el system for assessing the ability to protect against physio logically important reactive oxygen species such as superoxide, hydro xyl radical, and hypochlorou s acid, bec ause the antioxi dant activity determined by this assay reflects only an abilit y to scav enge wat er-soluble pero xyl radicals deri ved from the decomposition of AAPH. Thus, an ability to scavenge peroxyl radic als gives only a limited part of the plasma capacity to react with physiologic reactive oxidants, a fact that shou ld be kept in mind when interpreting the results obtain ed by the TRAP assay (32) . Figures 1 and 2 clearly illustrate that, with clinic al impro vement after the initiation of peni cillamine therap y, antioxidant lev els wer e restored to normal in both patients 1 and 2, and the TRAP values also incre ased to become comparable to those in control children. Moreover, the plasma allantoin concentration decreased to the control level and there was a converse increa se of uric acid . Bas ed on these observations, we propose that the monitoring of plasm a urate and allantoin concentrations may provid e a useful index for assessment of the clinic al status in patients with Wilson 's disease . Despite its somew hat limited value, the TRAP assay may also serve as anoth er index for the follow-up of Wilsonian patients .
In conclu sion , we demonstrated the possible involvement of oxida tive processes contributed to the development of complications in Wilson 's disease, but additional studies are needed for the precise mech anism to be clarified.
